Cost Benefit and Cost Effectiveness of Antifungal Prophylaxis in Immunocompromised Patients Treated for Haematological Malignancies: Reviewing the Available Evidence

Author： Pechlivanoglou Petros  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.29, Iss.9, 2011-09, pp. : 737-751

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Incremental Cost Effectiveness of Prophylaxis for Cytomegalovirus Disease in Patients with AIDS

By Kempen J.H.  

PharmacoEconomics, Vol. 19, Iss. 12, 2001-01 ,pp. : 1199-1208

Adis International

Access to resources Recommend Favorite

An introduction to cost-effectiveness and cost–benefit analysis of pharmacogenomics

By Phillips Kathryn A   Veenstra David   Bebber Stephanie Van   Sakowski Julie  

Pharmacogenomics, Vol. 4, Iss. 3, 2003-05 ,pp. : 231-239

Future Medicine

Access to resources Recommend Favorite

Cost-effectiveness of antibiotic prophylaxis for bacterial arthritis

By Krijnen Pieta   Schaardenburg Dirkjan van   Kaandorp Carola  

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 3, 2002-03 ,pp. : 271-275

Informa Healthcare

Access to resources Recommend Favorite

Cost Effectiveness of Itraconazole in the Prophylaxis of Invasive Fungal Infections

By Robin de Vries  

PharmacoEconomics, Vol. 26, Iss. 1, 2008-01 ,pp. : 75-90

Adis International

Access to resources Recommend Favorite

Lifetime Cost-Utility Analysis of Patients with Refractory Epilepsy Treated with Adjunctive Topiramate Therapy: Cost-Effectiveness in Refractory Epilepsy

By Maltoni S.   Messori A.  

Clinical Drug Investigation, Vol. 23, Iss. 4, 2003-01 ,pp. : 225-232

Adis International

Access to resources Recommend Favorite